The company chose as the scenario of the presentation the Congress of the American Society of Oncology Clinic (disgust), which is celebrated from May 30 to June 3 in Chicago, United States.
Astrazeneca stressed that it is the first essay in a decade that demonstrates An improvement in the results of frontline therapy (1l) in a wide range of Patients with breast cancer Metastasic Her2+, which is characterized by its high aggressiveness and high proliferation capacity.
This type of cancer represents between 15% and 20% of the total of cases of diagnosed breast cancer and is characterized by its high aggressiveness and high proliferation capacity.
The Survival without progression rose to 40.7 months In the group treated with ENHERU and PERUTUZUMAB, compared to 26.9 months registered with the standard solution.
The National Institute of Cancer of the USA. The disease does not get worse. In a clinical trial, this indicator is used to determine the effectiveness of a new treatment.
Destiny -breast009 is a Phase III clinical trial, destined to prove the security and efficacy of a treatment new compared to the standard.
“Treating in the initial stages of the disease can make a greater difference. If you approve, all the Patients with metastatic breast cancer HER2+ could be eligible to receive in someu at some point in their treatment, ”said Susan Galbraith, R&D Executive Vice President in Astrazeneca oncology, during a telematic press conference.
First -line therapy is the first treatment used for a disease and, according to the National Cancer Institute, is often part of a set of treatments, such as surgery followed by chemotherapy and radiation; But, when used in isolation, it is considered the best available option.
Galbraith said that, although Side effects were observednew security concerns did not arise, which makes this treatment a new standard potential in the care of this type of cancer.
For his part, Dave Fredrickson, Executive Vice President of Astrazeneca in the Oncology Business Unit, stressed that Destiny-BREAST09 demonstrates the Importance of applying antibody-pest conjugates (ADC) in earlier stages of treatment to obtain better results.
According to the pharmacist, ADC are medications that Manage chemotherapeutic agents directly to cancer cells by a biker attached to a monoclonal antibody.
“When cancer is detected in time and the right time to modify the treatment is identified, we have the best opportunity to prevent recurrence and seek the cure,” Fredrickson concluded.